Embecta Corp. · Surgical & Medical Instruments & Apparatus

EMBC

Low riskNext report: Around Nov 24 (est.)

View price ↗

The short version

A profitable company with shrinking sales. Institutions are trimming.

Going well

Pays a 8.8% dividend yield
Profitable
Brings in more cash than it spends

Money moves

No insider buying or selling in the last 30 days
Institutions cut 17% from their holdings in the quarter ending June 2026 (138 bought, 145 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$6.81+1.6% that day

Company value: $386M; Share price times all shares
Price vs profit (P/E): 4.6x; You pay about $5 for each $1 of yearly profit
Price vs sales: 0.38x; Company value is 0.38 times a year of sales
Dividend yield: 8.8%; Yearly dividend as a share of today's price
Cash vs value: 56%; A big cushion: cash is a large part of what the company is worth
Debt vs value: 362%; Owes more than the whole company is worth

From EMBC's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$271.7M-8.1% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $1.0B, down 7.6% from the 12 months before. Over 5 years, sales shrank about 0.1% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of EMBC. Starting points are the company's recent numbers.

Sales growth-8% a yearRecently: -7.6% a yearProfit margin9%Last 12 months: 8.6%P/E at the end8xToday: 4.6x. Many steady companies trade at 12x to 25xShare count change+1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$671M

Profit in 5 years$60M

Price these guesses point to$8.12+19% vs $6.81 todayAbout +3.6% a year, before dividends

What today's price needs: with a 9% margin and a 8x P/E, sales could shrink about 11% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

3/6Mixed

MissDebt under half of equityNot relying on borrowed money.Owes more than it owns
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.8.8%
PassProfitable every yearSteady profits, not one good year.6 of 6 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$182.4M
MissShare count not growingNot diluting owners. Falling means buybacks.+2.5% in 3 years
PassGross margin 40%+Pricing power: sells for well above what it costs to make.62.6%

Revenue: $1.1B; -3.8% vs prior year
5-year growth: -0.1%/yr; revenue, per year
Total debt: $1.4B
Current ratio: 2.64x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 7

Revenue: $271.7M; -8.1% YoY
EPS: $0.36; vs $0.78
Op. margin: 17.9%; -13.9 pts
Gross margin: 56.4%; -10.3 pts
Free cash flow: $40.7M
Share count: 0.0%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.9
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Distributing-17.2%

Institutions cut 17.2% from their holdings. 138 bought, 145 sold.

Shares held by institutions50.4M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

-0.4%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

Owes more than it owns

Shares outstandingLatest reported

57M

Earnings reports

Last 12

Next reportAround Nov 24 (est.)Estimated from the same quarter last year

Results filedAug 7
Results filedMay 5
Results filedFeb 5
Results filedNov 25, 2025
Results filedAug 8, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (passive)Aug 14 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

SoldMilton Mayo MorrisDirector

6,293 shares at $5.88 · $37K

-10% of holdings
Now owns 53,828 shares
Not a pre-planned sale
Filed 4 days after trade

Sep 4Form 4 ↗

Planned insider saleSep 4 · Form 144 ↗5%+ holder update (passive)Aug 14 · Form SCHEDULE 13G/A ↗

BoughtRobert J. HombachDirector

45,000 shares at $4.97 · $224K

+70% of holdings
Now owns 109,587 shares
Filed 1 day after trade

Aug 12Form 4 ↗

BoughtJeffrey Z MannPres, Pharm Svc&Prod Mgmt, CLO

20,000 shares at $4.99 · $100K

+8% of holdings
Now owns 262,915 shares
Filed 1 day after trade

Aug 12Form 4 ↗

BoughtJacob ElguiczeSVP and CFO

20,000 shares at $4.67 · $93K

+7% of holdings
Now owns 309,139 shares
Filed 1 day after trade

Aug 12Form 4 ↗

BoughtDevdatt KurdikarPresident and CEO, Director

30,000 shares at $4.70 · $141K

+4% of holdings
Now owns 804,919 shares
Filed 1 day after trade

Aug 12Form 4 ↗

Shares withheld for taxesJean CasnerChief Human Resources Officer

1,480 shares at $4.42 · $7K

-2% of holdings
Now owns 85,915 shares
Filed 2 days after trade

Aug 9Form 4 ↗

Earnings resultsAug 7 · Form 8-K ↗Quarterly reportAug 7 · Form 10-Q ↗Employee stock plan registrationAug 7 · Form S-8 ↗Current reportJul 31 · Form 8-K/A ↗5%+ holder update (passive)Jul 8 · Form SCHEDULE 13G/A ↗Insider tradeJun 2 · Form 4 ↗5%+ holder update (passive)May 27 · Form SCHEDULE 13G/A ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page